Immunotherapies: The blockade of inhibitory signals

International Journal of Biological Sciences

Volumn 8, Issue 10, 2012, Pages 1420-1430

  Wu, Yan Ling ^a   Liang, Jing ^b   Zhang, Wen ^b   Tanaka, Yoshimasa ^c   Sugiyama, Hiroshi ^c  

^a ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

BTLA; CTLA 4; Immunotherapy; Inhibitory receptors; PD 1

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; BTLA PROTEIN, MOUSE; CD274 PROTEIN, MOUSE; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; PD 1 ANTIGEN, MOUSE; PD-1 ANTIGEN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD274; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; CTLA-4 ANTIGEN; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MICE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION; TRANSPLANTATION IMMUNOLOGY;

EID: 84869787349     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5273     Document Type: Review

References (102)

1. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003; 21: 305-334.
2. Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today. 1998; 19: 27-30.
3. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition of T cell responses: mechanisms and manipulation in tumor immunother-apy. Annu Rev Immunol. 2001; 19: 565-594.
4. Jain N, Nguyen H, Chambers C, et al. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoim-munity. PANS. 2010; 107: 1524-1528.
5. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD-28-dependent T cell activation. J Exp Med. 1996; 183: 2541-2550.
6. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. J Immunol. 1994; 1: 405-413.
7. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol, 2001; 19: 565-594.
8. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA-4 co-receptor signaling. Nature Rev Immunol. 2003; 3: 544-556.
9. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 co-stimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001; 19: 225-252.
10. + T cells. Adv Immunol. 2003; 81: 331-371.
11. + regulatory T cell function. Science 2008; 322: 271-275.
12. Cross AH, Girard TJ, Giacoletto KS, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest. 1995; 95: 2783-2789.
13. Knoerzer DB, Karr RW, Schwartz BD, et al. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995; 96: 987-993.
14. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006; 144: 865-876.
15. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994; 265: 1225-1227.
16. Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rat. J Am Soc Nephrol. 2002; 13: 519-527.
17. Dong VM, Yuan X, Coito AJ, et al. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allografts rejection. Transplantation. 2002; 73: 1310-1317.
18. Guillonneau C, Séveno C, Dugast AS, et al. Anti-cd28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol. 2007; 179: 8164-8171.
19. Urakami H, Ostanin DV, Hunig T, et al. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc. 2006; 38: 3244-3246.
20. Yu XZ, Bidwell SJ, Martin PJ, et al. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol. 2000; 164: 4564-4568.
21. Yu XZ, Albert MH, Martin PJ, et al. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest. 2004; 113: 1624-1630.
22. Dengler TJ, Szabo G, Sido B, et al. Prolonged allograft survival but no tolerance infuction by modulation CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation. 1999; 67: 392-398.
23. Pearson TC, Alexander DZ, Winn KJ, et al. Transplantation tolerance induced by CTLA-4-Ig. Transplantation. 1994; 57: 1701-1706.
24. Zhai C, Yu L, Zhu H, et al. Porcine CTLA-4-Ig prolong islet xenografts in rats by downregulating the direct pathway of T-cell activation. Xeno-transplantation. 2011; 18: 40-45.
25. Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L, et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with Rheumatoid Arthritis. J. Clin. Immunol. 2011; 31: 588-595.
26. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-1736.
27. Peggs KS, Quezada SA, Korma AJ, et al. Principles and use of an-ti-CTLA-4 antibody in human cancer immunothearpy. Curr Opin Immunol. 2006; 18: 206-213.
28. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor anctivity of anti-CTLA-4 antibodies. J Exp Med. 2009; 206: 1717-1725.
29. Mokyr MB, Kalinichenko T, Gorelik L, et al. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-beating mice. Cancer Res. 1998; 58: 5301-5304.
30. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005; 11: 728-734.
31. Sutmuller RPM, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001; 194: 823-832.
32. Suarez N, Alfaro C, Dubrot J, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer. 2011; 129: 374-386.
33. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003; 63: 3281-3288.
34. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and my-eloid cells within B16 melanoma tumors. PANS. 2010; 107: 4275-4280.
35. Curran MA, Kim M, Montalvo W, et al. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T cell infiltration, proliferation and cytokine production. PLoS ONE. 2011; 6: 1-11.
36. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-CTLA-4 monoclonal antibody with multiple peptides and Montanide ISA 51 for patients with resected stages III/IV melanoma. J Clin Oncol. 2005; 23: 741-750.
37. Phan GQ, Yang JC, Aherry RM, et al. Cancer regression and autoim-munity induced by cytotoxic T lymphocyte-associated antigen antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci. 2003; 100: 8371-8377.
38. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol. 2011; 22: 991-993.
39. Hersh EM, Weber J, Powderly J, et al. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. J Clin Oncol. 2004; 22: s7511.
40. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Pron Natl Acad Sci. 2003; 100: 4712-4717.
41. + T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011; 60: 1137-1146.
42. Bachmann MF, Waterhouse P, Speiser DE, et al. Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells. J Immunol. 1998; 160: 95-100.
43. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439: 682-687.
44. Leng Q, Bentwich Z, Magen E, et al. CTLA-4 upregulated during HIV infection: association with anergy and possible target for therapeutic intervention. Aids. 2002; 16: 519-529.
45. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007; 8: 1246-1254.
46. Cao J, Zhang L, Huang S, et al. Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb Pathog. 2011; 51: 262-267.
47. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J.1992; 11: 3887-3895.
48. Nishimura H, Nose M, Hiai H, et al. Develpoment of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM mo-tif-carring immunoreceptor. Immunity. 1999; 11: 141-151.
49. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardio-myopathy in PD-1 receptor-deficient mice. Science. 2001; 291: 319-322.
50. Chen Y, Wu S, Guo G, et al. Programmed death (PD)-1-dificient mice are extremely sentitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog. 2011; 7: e1001347.
51. Achleiner A, Clark ME, Bienzle D. T-regulatory cells infected with immunodeficiency virus up-regulate programmed death-1(PD-1). Vet Immunol Immunopathol. 2011; 143: 307-313.
52. Chen J, Wang XM, Wu XJ, et al. Intrahepatic levels of PD-1/PD-L1 correlate with liver inflammation in chronic hepatitis B. Inflamm Res. 2011; 60: 47-53.
53. + T cell responses. Vaccine. 2011; 29: 3169-3176.
54. Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011; 6(9): e23621.
55. + T cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011; 128: 887-896.
56. Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Im-munother. 2011; 60: 965-974.
57. + T lymphocytes infiltrating human tumors. PLoS One. 2011; 6: e17621.
58. Wang SC, Chen YJ, Ou TT, et al. Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan. J Clin Immunol. 2006; 26: 506-511.
59. Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The Programmed Death1/Programmed Death Ligand 1 Inhibitory Pathway Is Up-Regulated in Rheumatoid Synovium and Regulates Peripheral T Cell Responses in Human and Murine Arthritis. Arthritis Rheum. 2010; 62: 1870-1880.
60. Ni R, Ihara K, Miyako K, et al. PD-1 gene haplotype is associated with the development of type diabetes I mellitus in Japanese children. Hum Genet. 2007; 121: 223-232.
61. Ding H, Wu X, Wu J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS costimulation supresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol. 2006; 118: 258-267.
62. Hirata S, Senju S, Matsuyoshi H, et al. Prevention of experiment autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol. 2005; 174: 1888-1897.
63. Schreiner B, Mitsdoerffer M, Kieseier BC, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modu-latory effect in multiple sclerosis. J Neuroimmunol. 2004; 155: 172-182.
64. Zhou Q, Xiao H, Liu Y, et al. Blockade of programmed death -1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immuno. 2010; 185: 5082-5092.
65. Sierro SR, Donda A, Perret R, et al. Combination of lentivector immunization and low-dose chemotherapy of PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol. 2011; 41: 2217-2228.
66. Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007; 19: 1223-1234.
67. Borkner L, Kaiser A, van de Kasteele W, et al. RNA interference targeting programmed death receptor-1 improves immune function of tumor-specific T cells. Cancer Immunol Immunother. 2010; 59: 1173-1183.
68. Iliopoulos D, Kavousanaki M, Ioannou M, et al. The negative costimu-latory molecule PD-1 modulates the balance between immunity and tolerance via miR-21. Eur J Immunol. 2011; 41: 1754-1763.
69. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of an-ti-PD-1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465.
70. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-L1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454.
71. Pardoll DM. The blockade of immune immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.
72. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443: 350-354.
73. Ma CJ, Ni L, Zhang Y, et al. PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in mono-cytes/macrophages during chronic hepatitis C virus infection. Immunology. 2010; 132: 421-431.
74. + t Cell exhaustion during chronic viral infection by multiple inhibitory receptors. Nat Immunol. 2009; 10: 29-37.
75. Das S, Suarez G, Beswick EJ, et al. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol. 2006; 176: 3000-3009.
76. Smith P, Walsh CM, Mangan NE, et al. Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J Immunol. 2004; 173: 1240-1248.
77. Monaghan SF, Thakkar RK, Chung CS, et al. Lack of programmed cell death receptor (PD)-1 leads to improved survival in a murine model of indirect acute lung injury. J Am Coll Surg. 2010; 211: s52.
78. Peña-Cruz V, McDonough SM, Diaz-Griffero F, et al. PD-1 on immature and PD-1 ligands on migratory human langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol. 2010; 130: 2222-2230.
79. Özkaynak E, Wang L, Goodear A, et al. Programmed death-1 targeting can promote allograft survival. J Immunol. 2002; 169: 6546-6553.
80. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003; 171: 1272-1277.
81. Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negtive signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation. 2003; 76: 994-999.
82. Bernard D, Hansen JD, Pasquier LD, et al. Costimulatory reseptors in jawed vertebrates: conserved CD28, odd CTLA-4 and multiple BTLAs. Dew Comp Immunol. 2007; 31: 255-271.
83. Chemnitz JM, Lanfranco AR, Braunstein I, et al. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol. 2006; 176: 6603-6614.
84. Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al. A co-receptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. PNAS USA. 2005; 102: 1116-1121.
85. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003; 4: 670-679.
86. Compaan DM, Gonzalez LC, Tom I, et al. Attenuationg lymphocyte activity-the crystal structure of the BTLA-HVEM complex. J Biol Chem. 2005; 280: 39552-39561.
87. + T cell intrinsic homeostasis and memory cell generation. Nat Immunol. 2007; 8: 162-171.
88. Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirous entry mediator. Nat Immunol. 2005; 6: 90-98.
89. + T cells. J Immunol. 2005; 174: 3377-3385.
90. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimu-lation. J Immunol. 2007; 178: 6073-6082.
91. Lin SC, Kuo CC, Chan CH. Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. J Biomed Sci. 2006; 13: 853-860.
92. Fu Z, Li D, Jiang W, et al. Association of a BTLA gene polymorphism with the risk of malignant breast cancer in Chinese women of Hei-longjiang Province. Breast Cancer Res Treat. 2010; 120: 195-202.
93. Wang Y, Subudhi SK, Anders RA, et al. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest. 2005; 115: 711-717.
94. Lin SC, Kuo CC, Chan CH. Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. J Biomed Sci. 2006; 13: 853-860.
95. Oya Y, Watanabe N, Owada T, et al. Development of autoimmune hepatitis-like disease and autoantibody production to nuclear antigens in mice lacking B and T lymphocyte attenuator (BTLA). Arthritis Rheum. 2008; 58: 2498-2510.
96. Oya Y, Watanabe N, Kobayashi Y, et al. Lack of B and T lymphocyte attenuator exacerbates autoimmune disorders and induces Fas-independent liver injury in MRL-Ipr/lpr mice. Int Immunol. 2011; 23: 335-344.
97. Pierer M, Schulz A, Rossol M, et al. Herpesvirus Entry Mediator-Ig Treatment during Immunization Aggravates Rheumatoid Arthritis in the Collagen-Induced Arthritis Model. J Immunol. 2009; 182: 3139-3145.
98. + T cells that can be partially reversed by vaccination. J Clin Invest. 2010; 120: 157-167.
99. Lepenies B, Pfeffer K, Hurchla MA, et al. Ligation of B and T Lymphocyte Attenuator Prevents the Genesis of Experimental Cerebral Malaria. J Immunol. 2007; 179: 4093-4100.
100. Tao R, Wang L, Han R, et al. Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts. J Immunol. 2005; 175: 5774-5782.
101. Granger SW, Rickert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev. 2003; 14: 289-296.
102. Truong W, Plester JC, Hancock WW, et al. Combined Coinhibitory and Costimulatory Modulation with Anti-BTLA and CTLA4Ig Facilitated Tolerance in Murine Islet Allografts. Am J Transplant. 2007; 7: 2663-2674.